Avita Medical Ltd logo

Avita Medical Ltd(RCEL)

upturn advisory logo
ADVISORIES YOU CAN VERIFY
QUALITY SIGNAL RECENCY
1-STAR RATING
Consider higher Upturn Star rating
BUY for 29 days
PROFIT SINCE LAST BUY
+45%
LAST CLOSE
$11.02
09/18/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close

Advisory Performance History (Simulated)Advisory Performance History info

Upturn Advisory & Investor View for RCEL

09/18/2026: RCEL (1-star) has a low Upturn Star Rating. Not recommended to BUY.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -39.08%
Avg. Invested days 27
Today’s Advisory Consider higher Upturn Star rating
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 09/18/2026

Upturn Scorecard

Upturn Star Rating

RCEL receives a 3-star rating, supported by available scored pillars. The rating is constrained by soft unit economics.

Company Fundamentals

RCEL has moderate overall fundamentals (3 stars), with soft financial health, solid growth momentum, and moderate ownership. In FY2025 versus FY2024, solid earnings growth (+21.4%) and solid revenue growth (+11.5%) are partially offset by soft cash generation (FCF margin -46.0%), soft profitability (net margin -67.8%), modest insider ownership of 1.52%.

Financial Health Rating

RCEL's financial health is supported by moderate efficiency, including operating-expense and cost-of-revenue discipline (opex 141.5% of revenue). Cash strength is soft (2 stars), which helps explain the 2-star overall score.

Growth Momentum Score

Free-cash-flow growth is RCEL's strongest growth driver at +43.5% FY2025 versus FY2024 (strong, 5 stars). Revenue growth (+11.5%, solid) and earnings growth (+21.4%, solid) are also constructive, though not equally high across every growth measure.

Ownership

Institutional ownership is 16.0% and approximately 98.5% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 1.52% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

Vanguard Capital Management, LLC 4.32%
BlackRock Inc 3.66%
Geode Capital Management, LLC 1.76%
State Street Corp 1.39%
Vanguard Fiduciary Trust Co 0.63%

Unit Economics (Per $1K Revenue)

RCEL generates approximately $821 of gross profit, $-594 of operating income, and $-460 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Strong cash conversion and healthy margins support the rating, although capital efficiency remains below the highest tier.

Economic Dimensions

Effective Tax Rate: -0.02% (Tax Credit)

Quantitative Style Profile

RCEL has a liquid profile. Elevated volatility is the primary drawback.

Style Classification

Quality Focused

Momentum LeaderValue-OrientedHigh VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 340.81M USD
Price to earnings Ratio -
1Y Target Price 12.31
Price to earnings Ratio -
1Y Target Price 12.31
Volume (30-day avg) 628.5K shares
Beta 2.02
52 Weeks Range 3.22 - 11.39
Updated Date 09/20/2026
52 Weeks Range 3.22 - 11.39
Updated Date 09/20/2026
Dividends yield (FY) -
Basic EPS (TTM) -1.44

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Advertisement

Valuation

Trailing PE -
Forward PE 10.29
Enterprise Value 376.61M
Price to Sales(TTM) 4.51
Enterprise Value 376.61M
Price to Sales(TTM) 4.51
Enterprise Value to Revenue 4.98
Enterprise Value to EBITDA -6.17
Shares Outstanding 30.93M
Shares Floating 30.47M
Shares Outstanding 30.93M
Shares Floating 30.47M
Percent Insiders 1.52
Percent Institutions 16.03

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

About Avita Medical Ltd

Exchange NASDAQ
Headquarters Valencia, CA, United States
IPO Launch date 2019-10-01
President, CEO & Executive Director Mr. Cary G. Vance
Sector Healthcare
Industry Medical Devices
Full time employees 226
Full time employees 226

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company sells and distributes PermeaDerm, a biosynthetic wound matrix and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.